Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

BoA Keeps 'Strong Buy' on Johnson & Johnson

Banc of America reiterates strong buy and a $75 target on Johnson & Johnson (JNJ).

Analyst Kurt Kruger says he views J&J as a net acquiror; therefore, with Pfizer lower on a near term dilutive acquisition announcement, he thinks a large factor in Monday's stock price weakness is the pending consolidation in the pharma sector.

If J&J were to make an acquisition, Kruger says he thinks J&J would target the cardiovascular area, which would build a franchise for its coated stent products. He says Amgen's attack on the safety of J&J's anemia drug Eprex, which is linked to blood disorder, is not new news. Kruger looks for solid $0.58 second quarter earnings per share on Tuesday; and strong sales in the cardio and ortho markets. Shares are trading at a historically low 17 times the $2.69 2003 EPS.

blog comments powered by Disqus